MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Natera Inc

Open

SectorGezondheidszorg

151.85 -0.32

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

151.76

Max

155.06

Belangrijke statistieken

By Trading Economics

Inkomsten

-22M

-54M

Verkoop

36M

476M

EPS

-0.41

Winstmarge

-11.295

Werknemers

4,424

EBITDA

-27M

-46M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+26.23% upside

Dividenden

By Dow Jones

Volgende Winsten

8 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-890M

20B

Vorige openingsprijs

152.17

Vorige sluitingsprijs

151.85

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Natera Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 mei 2024, 14:49 UTC

Winsten
Populaire aandelen

Stocks to Watch Friday: TSMC, Novavax, Nvidia -- WSJ

Peer Vergelijking

Prijswijziging

Natera Inc Prognose

Koersdoel

By TipRanks

26.23% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 195 USD  26.23%

Hoogste 251 USD

Laagste 160 USD

Gebaseerd op 16 Wall Street-analisten die 12-maands prijsdoelen bieden voor Natera Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

16 ratings

16

Buy

0

Hold

0

Sell

Technische score

By Trading Central

147.24 / N/ASteun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Natera Inc

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.